The complete genome sequence of Chromobacterium violaceum reveals remarkable and exploitable bacterial adaptability

Chromobacterium violaceum is one of millions of species of free-living microorganisms that populate the soil and water in the extant areas of tropical biodiversity around the world. Its complete genome sequence reveals (i) extensive alternative pathways for energy generation, (ii) ≈500 ORFs for transport-related proteins, (iii) complex and extensive systems for stress adaptation and motility, and (iv) wide-spread utilization of quorum sensing for control of inducible systems, all of which underpin the versatility and adaptability of the organism. The genome also contains extensive but incomplete arrays of ORFs coding for proteins associated with mammalian pathogenicity, possibly involved in the occasional but often fatal cases of human C. violaceum infection. There is, in addition, a series of previously unknown but important enzymes and secondary metabolites including paraquat-inducible proteins, drug and heavy-metal-resistance proteins, multiple chitinases, and proteins for the detoxification of xenobiotics that may have biotechnological applications

Reflectância espectral e mineralogia de materiais formados sobre diabásio Spectral reflectance and mineralogy of soil materials developed from diabase

O presente estudo teve por objetivo caracterizar diferentes fases de intemperismo de um solo e relacioná-las com seu comportamento espectral. Um perfil pedológico desenvolvido sobre diabásio da região de Capivari-SP, foi descrito morfologicamente, identificando-se seis fases de alteração. Os atributos analisados foram granulometria, composição química e mineralógica. A reflectância espectral do solo foi avaliada em laboratório através de espectrorradiômetro na faixa de 300 a 2500 nm. O perfil apresentou grau de intemperismo moderado, o que foi evidenciado pela alta relação silte/argila observada abaixo do horizonte Bi. Os horizontes subsuperficiais também apresentaram alto teor de nutrientes, especialmente P, Ca e Mg, que estavam relacionados com a presença em subsuperfície de saprolito com razoável reserva de minerais intemperizáveis. A evolução dos minerais primários iniciou pela formação de óxidos de ferro e de argilas 2:1, como vermiculita ou vermiculita-esmectita, que foram transformadas em caulinita e gibbsita em direção ao topo do perfil. Na medida em que ocorreram alterações na composição mineralógica no perfil, foram verificadas variações nos dados espectrais. Basicamente a reflectância foi influenciada diferenciadamente pela ocorrência de óxidos de ferro, diferentes tipos de argilas e minerais primários como piroxênios e magnetita.<br>The aim of this study was to characterize soil materials with different degrees of weathering and then associate their composition with their spectral behavior. One pedological profile developed from diabase was studied in Capivari-SP, Brazil. The morphological description allowed to separate six phases of rock-soil alteration. Afterwards, granulometry, chemical and mineralogical analysis were carried out. The soil spectral reflectance was evaluated with a laboratory spectroradiometer using the wavelength range of 300 to 2500 nm. The profile was moderately weathered as evidenced by a high silt/clay ratio, found below the Bi horizon. Subsurface horizons also presented high nutrient status, especially for P, Ca and Mg, which was related to the occurence of saprolite with an abundance of easily weathered minerals. The mineral evolution began with the precipitation of iron oxides and 2:1 clay minerals, like vermiculite and vermiculite-smectite, and this led to the formation of kaolinite and gibbsite in the upper part of the soil profile. Spectral behavior generally was in conformity with their mineralogical composition, pointing out to the presence of iron oxides, various groups of clays and primary minerals, such as pyroxenes and magnetite

Resumos concluídos - Ciências Biomédicas

Resumos concluídos - Ciências Biomédica

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial

Background: Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor. Methods: The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population). Findings: Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8–3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74–0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, p interaction=0·16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3·1%] with ticagrelor vs 183 (3·3%) with placebo; HR 0·96 [95% CI 0·78–1·18], p=0·68), as well as all-cause death (282 [5·1%] vs 323 [5·8%]; 0·88 [0·75–1·03], p=0·11). TIMI major bleeding occurred in 111 (2·0%) of 5536 patients receiving ticagrelor and 62 (1·1%) of 5564 patients receiving placebo (HR 2·03 [95% CI 1·48–2·76], p<0·0001), and fatal bleeding in 6 (0·1%) of 5536 patients with ticagrelor and 6 (0·1%) of 5564 with placebo (1·13 [0·36–3·50], p=0·83). Intracranial haemorrhage occurred in 33 (0·6%) and 31 (0·6%) patients (1·21 [0·74–1·97], p=0·45). Ticagrelor improved net clinical benefit: 519/5558 (9·3%) versus 617/5596 (11·0%), HR=0·85, 95% CI 0·75–0·95, p=0·005, in contrast to patients without PCI where it did not, p interaction=0·012. Benefit was present irrespective of time from most recent PCI. Interpretation: In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk